Mast cells may contribute to the pathogenesis of eosinophilic esophagitis (EoE), but their role in diagnosis is unknown. Our aim was to determine whether tryptase staining of esophageal mast cells differentiates EoE from gastroesophageal refl ux disease (GERD) and has utility for diagnosis of EoE.
INTRODUCTION
Eosinophilic esophagitis (EoE) is an increasingly recognized clinicopathologic condition defi ned in recent guidelines as esophageal dysfunction and esophageal eosinophilia in the absence of other potential causes including gastroesophageal refl ux disease (GERD) ( 1 ) . In practice, however, it can be challenging to diff erentiate these two conditions because the clinical and histopathologic features of EoE and GERD overlap substantially. For example, symptoms of EoE include dysphagia, food impaction, and heartburn, complaints commonly found in the GERD populations ( 1 -7 ) . Th e histologic hallmark of EoE is esophageal eosinophilia, but this is also not specifi c and the high numbers of eosinophils can be seen in GERD as well ( 8 -10 ) .
Mast cells have been implicated in EoE pathogenesis in several studies, and could hold promise as a specifi c tissue marker of EoE. Increased staining for mast cells has been demonstrated in patients with EoE compared with those with GERD and to normal controls ( 11 -18 ) . Mast cell-associated genes are upregulated in EoE ( 13, 18 ) , and mast cells produce interleukin-13 and transforming growth factor (TGF)-β , which have been implicated in eosinophil migration and fi brosis, respectively ( 19 -23 ) , however, the potential role of mast cells in diagnosing EoE is unknown.
Th e aim of this study was to determine whether the presence of tryptase-positive mast cells in the esophageal epithelium could diff erentiate EoE from GERD and, if so, to determine the utility of the assay for diagnosis of EoE. We hypothesized that patients with EoE would have a greater number of esophageal mast cells than GERD patients, and that increasing numbers of mast cells would predict EoE case status.
METHODS

Study design and patients
Th is was a case -control study of patients from the UNC EoE Clinicopathologic database from 2000 to 2007. Details of the development of this database and patient characteristics have been previously reported ( 7 ) .
Cases were patients of any age who had newly diagnosed EoE as defi ned by recent consensus guidelines ( 1 ) . Th ese cases had at least one typical symptom of esophageal dysfunction (e.g., dysphagia, food impaction, heartburn, or feeding intolerance); at least 15 eosinophils per high-power fi eld (eos / hpf) on esophageal biopsy; and had other causes of esophageal eosinophilia, including refl ux disease, excluded. GERD was excluded in EoE cases by documenting persistent esophageal eosinophilia despite acid suppression at the time of biopsy ( n = 32), by documenting persistent esophageal eosinophilia despite prior symptoms refractory to high-dose acid suppression ( n = 18), or with negative pH monitoring ( n = 4). Of note, these cases had previously been extensively characterized with confi rmation of the diagnosis of EoE ( 7 ) .
Controls were GERD patients who underwent esophagogastroduodenoscopy and biopsy during the same time frame as the cases. GERD patients were defi ned by at least one typical symptom, including heartburn, regurgitation, pain, or, in children, failure to thrive, which was the primary indication for the procedure, and which responded to anti-secretory therapy with either a proton pump inhibitor or a H 2 receptor blocker. In addition, infl ammation, including at least 1 eos / hpf, was required on biopsy, and other potential or competing causes of the presentation were excluded by the clinical evaluation. We required some degree of eosinophilia in our GERD control population to generate a clinically ambiguous group in whom EoE might be misdiagnosed, and where the diagnostic challenge to the clinician was greatest. Such a group would presumably benefi t from an assay to diff erentiate GERD from EoE.
Data sources and histology review
Clinical data were extracted from electronic medical records and endoscopy reports. Covariates assessed included demographics (age at diagnosis, gender, and race); symptom complex; coexisting atopic disease (allergic rhinitis or sinusitis, documented food allergy (demonstrated by either symptomatic evidence of allergy with reintroduction of a food or by testing directed by an Allergist), or asthma); and endoscopic fi ndings (rings, strictures, a narrow-caliber esophagus, linear furrows, white plaques or exudates, erosions, decreased vascularity, erosive esophagitis, ulceration, and hiatal hernia).
Archived pathology slides were rereviewed by the study pathologists to determine eosinophil counts according to our validated protocol ( 24 ) . In brief, slides were masked as to case and control status, and the maximum eosinophil density (eosinophils / mm 2 ) was determined aft er examination of fi ve microscopy fi elds. For purposes of comparison to previous studies, eosinophil density was then converted to eos / hpf for an assumed hpf size of 0.24 mm 2 , the size of an average fi eld as reported in the literature ( 5 ) .
Immunohistochemistry and mast cell counts
Formalin-fi xed paraffi n-embedded tissue blocks were masked to case and control status, sectioned (5 μ m thick), and randomly sorted. Immunohistochemistry was performed using a high volume automated system (Dako Autostainer; Dako, Carpinteria, CA) according to the standard protocol. Slides were deparaffi nized with xylene, steam-treated for antigen retrieval (Target Retrieval Solution; Dako), incubated with a mouse anti-human mast cell tryptase primary antibody (Clone AA1; 1:500 dilution; Dako), incubated with a peroxidase-labeled anti-mouse polymer secondary antibody (Envision; Dako), stained with a diaminobenzidine chromogen (DAB; Innovex Biosciences, Richmond, CA), and then counterstained with hematoxylin.
In a protocol identical to that for eosinophil counts, the immunohistochemistry glass slides were scanned and converted to digital slides, and viewed with Aperio ImageScope (Aperio Technologies, Vista, CA) ( 24 ) . Th e maximum density of tryptase-positive cells in the esophageal epithelial layer, measured in mast cells / mm 2 , was then determined aft er examination of fi ve microscopy fi elds. Th is quantitative measure of tryptase-positive mast cell density was the primary predictor variable for the study. In addition, we assessed the mucosal and biopsy distribution of mast cells, and made an assessment of staining intensity, which ranged from grade 0, or no staining, to grade 4, or diff use staining ( Figure 1 ). Th ese are presented to provide examples of the overall range of possible staining results.
Statistical analysis
Statistical analysis was performed using Stata version 9 (Statacorp, College Station, TX). Descriptive statistics were used to summarize the characteristics of the cases and controls. Bivariate analysis was performed with χ 2 for categorical variables, and t -tests or Wilcoxon rank-sum tests for continuous variables as appropriate. Correlation between mast cell and eosinophil counts was calculated by Pearson ' s Rho (R). To assess the eff ect of potential confounding factors, we performed two additional post hoc analyses. First, we limited the control group to only those patients with erosive esophagitis, assuming that this was a set of patients with defi nitive GERD. Second, we performed logistic regression controlling for clinical, endoscopic, and histologic factors to explore whether there was an additional benefi t of tryptase staining.
Receiver operating characteristic (ROC) curves were constructed using EoE case status as defi ned by the consensus diagnostic guidelines as the gold standard ( 1 ) . Th e area under the curve (AUC) was calculated and compared for three diff erent models predicting EoE case status: mast cell density alone; eosinophil count alone; and both mast cell and eosinophil levels. To contextualize the AUC, we calculated sensitivity, specifi city, and positive and negative likelihood ratios under fi ve conditions: for mast cell density alone, using a cutpoint that maximized sensitivity and specifi city in this dataset; for eosinophil count alone, fi rst using a cutpoint that maximized sensitivity and specifi city in this dataset, and then using a cutpoint of 15 eos / hpf, as per the current diagnostic guidelines ( 1 ); and for both mast cell and eosinophil levels, fi rst using the cutpoint for each that maximized sensitivity and specifi city in this dataset, and then using a cutpoint of 15 eos / hpf, as per diagnostic current guidelines.
Th is study was approved by the UNC Institutional Review Board.
RESULTS
Study subject characteristics
A total of 54 EoE cases and 55 GERD controls were identifi ed for this study ( Table 1 ). In comparison to the GERD controls, cases of 
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EoE were younger at diagnosis (24 vs. 34 years; P = 0.02), and had more dysphagia (70 vs. 31 % ; P < 0.001) and food impaction (28 vs. 2 % ; P = 0.001). Th e EoE cases also had more atopic diseases and food allergies. On endoscopy, EoE patients were more frequently found to have rings, esophageal narrowing, linear furrows, white plaques, and decreased vascularity. Th e GERD patients more commonly had a hiatal hernia. On histologic examination, the maximum eosinophil count was higher in the EoE group compared with the GERD group (146 eos / hpf vs. 20 eos / hpf; P < 0.001). EoE patients also had more eosinophil degranulation, microabscesses, and spongiosis ( Table 1 ). As expected with the defi nition of the control group, esophageal eosinophilia was prominent in the GERD patients, mirroring the clinical situation in which EoE and GERD can be confused.
Tryptase staining in cases and controls
Th ere were signifi cant diff erences in immunohistochemistry staining between the case and control groups in both the quantitative and the qualitative measures ( Table 2 ) . Th e maximum density of tryptase-positive mast cells was signifi cantly higher in the EoE group as compared with the GERD group (162 vs. 67; P < 0.001). Similarly, the qualitative staining intensity was signifi cantly higher in the EoE group. Although mast cells tended to have a basal location in both groups, they were more diff usely distributed throughout the entire biopsy specimen in the EoE group (41 vs. 7 % ; P < 0.001). A graphic representation of the tryptase staining distributions ( Figure 2 ) demonstrates that the groups have a substantially diff erent distribution, with relatively little overlap. Th ese results were unchanged even aft er restricting the control ( P = 0.23), but there was a diff erence between the AUC for eosinophils and the AUC for the combination of mast cells and eosinophils ( P = 0.004), as well as between the AUC for mast cells and the AUC for the combination of mast cells and eosinophils ( P < 0.001). Th ese results were unchanged even aft er restricting the control group to just those patients with erosive esophagitis (data not shown). When tryptase staining was added to a multivariable model containing additional predictive factors such as patient age, dysphagia, food allergy, the presence of rings, furrows, white plaques, or a hiatal hernia on endoscopy, the maximum eosinophil count, and degranulating eosinophils or eosinophilic microabscesses, the AUC also increased from 0.92 to 0.97, but this was not signifi cant. An analysis of the operating characteristics of tryptase staining and eosinophil counts can help to put the ROC analysis into a clinical context ( Table 3 ) . A cutpoint of 96 mast cells / mm 2 maximized the sensitivity (80 % ) and specifi city (80 % ) of tryptase staining in this study population, with a corresponding positive and negative likelihood ratio of 4 and 0.25, respectively. For the eosinophil count that maximized these parameters, the results were similar, with a sensitivity of 80 % and specifi city of 84 % . Sensitivity increased and specifi city decreased if an eosinophil count of 15 eos / hpf was used for the cutoff . However, if mast cell density and eosinophil count were considered together, the sensitivity and specifi city increased to 91 and 95 % , respectively, with a positive and negative likelihood ratio of 18 and 0.09, respectively. group to just those patients with erosive esophagitis found on upper endoscopy (data not shown).
When the number of tryptase-positive mast cells was compared with the tissue eosinophil density ( Figure 3 ) , there was only a weak ( R 2 = 0.09), though statistically signifi cant, correlation.
Tryptase staining for diagnosis of EoE
To determine the utility of tryptase staining for diagnosis of EoE, ROC curves were constructed ( Figure 4 ). Using mast cell staining as the only parameter in the model yielded an AUC of 0.84 as compared with consensus diagnostic guidelines as the gold standard. Th e AUC for the combination of mast cell count and eosinophil count, but without any other clinical, endoscopic, or histologic features, was 0.96. Th e AUC for eosinophil count alone was 0.89. Th ere was no diff erence between the AUC for mast cells alone and the AUC for eosinophils alone 
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DISCUSSION
Th e diagnosis of EoE is based on demonstrating the correct presentation of clinical, endoscopic, and histologic fi ndings. Recent consensus guidelines have formalized the requirements for diagnosis, which were used as the gold standard in our study ( 1 ) . In particular, competing causes of esophageal eosinophilia must be excluded. In many instances, GERD is the most important differential diagnosis. Th e diff erentiation between GERD and EoE is one of the most challenging aspects of the diagnosis and management of EoE, because the clinical and pathologic fi ndings of EoE are not specifi c and can overlap substantially with features of GERD ( 1 -10 ) .
In this study, we used a case -control design to compare staining for tryptase-positive mast cells in a large group of EoE and GERD patients. Th e controls were specifi cally selected to have prominent infl ammation, including eosinophilia, on their esophageal biopsies in order to mirror the clinical situation in which it can be difficult to distinguish EoE from GERD. Th ere were several fi ndings of note. First, the esophageal epithelial density of tryptase-positive mast cells was signifi cantly higher in EoE patients compared with GERD patients. Although this result was also true for the qualitative staining intensity, we feel that the utility of the tryptase staining technique will be in its quantitative application as this approach is likely less subjective. Second, there was only weak correlation between esophageal eosinophil and mast cell levels. Th is weak correlation is highly desirable in an additional test for EoE, as it suggests that analysis of mast cells could add diagnostic information not gained from simple eosinophil counts. Th ird, the presence of elevated numbers of mast cells in the esophageal epithelium was predictive of EoE case status without considering any additional clinical, endoscopic, or histologic information, and the combination of mast cell and eosinophil counts almost perfectly diff erentiated EoE from GERD.
How can these results be interpreted in the context of what is known about mast cells in the pathogenesis of EoE? EoE is felt to be related to an allergen exposure triggering a T H 2 response in which interleukin-13 stimulates esophageal epithelial cells to produce eotaxin-3, which subsequently recruits eosinophils to the esophagus ( 25 ) . When eosinophils are activated by interleukin-5 and eotaxin-3, they release major basic protein, which in turn activates mast cells ( 25, 26 ) . Once activated, mast cells produce interleukin-13, which can propagate esophageal eosinophilia and eosinophil activation. Mast cells also produce TGF-β , which has been implicated in esophageal fi brosis related to EoE ( 19 -23 ). Blanchard et al. ( 13 ) performed EoE transcriptome analysis demonstrating that mast cell-associated genes, including carboxypeptidase A3, the high-affi nity IgE receptor, and mast cell tryptase-α , were upregulated in EoE, but similar to our fi nding, they showed only weak correlation ( R 2 = 0.18) between the eosinophil and mast cell counts. One could hypothesize that the eosinophil and mast cell counts need not be correlated, because a relatively small number of activated eosinophils could recruit a large number of mast cells. Th e same group has recently reported a more detailed analysis of the mast cell transcriptome, which in a small sample of patients diff erentiated EoE patients from controls, and carboxypeptidase A3 was again implicated as a key gene ( 18 ) .
Several other authors have demonstrated increased staining for mast cells in patients with EoE compared with those with GERD or normal controls. Straumann et al. ( 11 ) fi rst observed increased numbers of mast cells in eight adult EoE patients compared with three normal controls, and Gupta et al. ( 12 ) reported similar results in a small number of children. Kirsch et al. ( 14 ) examined 25 EoE patients, 22 GERD patients, and 22 healthy controls, all in a pediatric population., Th ey found a count of 26 mast cells / hpf in the EoE group and 8 in the GERD group. Although they did not report the size of the microscope hpf, if we assume it to be 0.24 mm 2 , the density of tryptase-positive cells would be 108 masts / mm 2 in the EoE group and 33 in the GERD group, similar in magnitude to the results we report. Two additional studies in adults with EoE yielded comparable results ( 15, 16 ) . Despite this previous work, none of the prior investigations assessed the utility of tryptase staining for diagnosis of EoE. Given the crucial need for an easily performed assay to help diff erentiate EoE from GERD with mucosal eosinophilia, mast cell staining is attractive for its simplicity, excellent performance characteristics, and nominal correlation with eosinophil counts. 
Study Highlights
WHAT IS CURRENT KNOWLEDGE
Th is study featured large numbers of well-characterized patients, quantitative analysis of immunohistochemistry slides, and was focused on a highly relevant clinical question -the diagnostic utility of mast cell staining in a diffi cult to diagnose population. Th e study also has some limitations. First, there could be misclassifi cation of cases and controls. As we studied EoE patients that were previously extensively characterized and felt to be defi nitive cases ( 7 ), we feel that disease misclassifi cation of EoE patients was minimal. Regardless, even if contamination occurred between the groups (GERD patients in the EoE group and vice versa ), results should be biased toward the null, and the reported association between mast cell density and EoE diagnosis actually underestimated. Th e choice of this control group is also supported by the fact that our results were unchanged even when we limited the controls to those with defi nitive GERD as defi ned by the presence of erosive esophagitis on upper endoscopy. Second, because the study is from a single center, the fi ndings may not be generalizable. Although it is reassuring that features of this EoE population are quite similar to those reported from other centers ( 27 -31 ) , a case -control study design may provide an optimistic assessment of test accuracy and the use of tryptase staining for EoE will need to be validated in other populations before it can be adopted for routine use, and eff orts to do so are underway. In addition, the use of a specifi c cutpoint for tryptase density was for illustrative purposes to calculate sensitivity, specifi city, and likelihood ratios in order to contextualize our results; we do not feel that this value should be adopted in clinical practice until further studies validate our fi ndings. Th ird, there has been recent controversy concerning several possible relationships between GERD and EoE, whether it is appropriate to require exclusion of refl ux to diagnose EoE, and possible anti-infl ammatory eff ects of proton pump inhibitors in patients with EoE ( 2, 32, 33 ) . Our single time point of analysis, as well as the poorly understood nature of any common pathogenic factors in EoE and GERD, limits any conclusions about the utility of tryptase staining in subjects with hybrid conditions. Finally, our study design did not address the functional role of the mast cell, be it active or passive, in the pathogenesis of EoE. Although the potential role of mast cells in the early pathogenesis of EoE is important and incompletely described, it can have utility as a biomarker for EoE whether it is an active player in pathogenesis or merely a passive bystander.
In conclusion, patients with EoE have substantially higher levels of tryptase-positive mast cells in the esophageal epithelium compared with GERD patients with esophageal eosinophilia. Staining for mast cell tryptase may provide added diagnostic value because it is complementary to the eosinophil count and has utility for diff erentiating EoE from GERD. Th erefore, should further work validate these results, adding mast cell tryptase to the diagnostic algorithm may improve upon the current diagnostic standards for EoE.
